S-Acetyl-Glutathione

Acetylated, GI-stable form of glutathione (GSH) that improves oral bioavailability over plain GSH by ~13× in plasma AUC (Fanelli 2018) but is rapidly deacetylated to free GSH on the way to cells — meaning the "direct delivery" pitch is mostly true at the cell membrane, weakly supported at the brain. For Dylan: SKIP-FOR-NOW (LOW confidence) — V4 NAC 1200 mg already supplies cysteine, the rate-limiting substrate for endogenous GSH synthesis, and crosses the BBB more cleanly with replicated brain RCTs. SAG is insurance-tier with subtle if any subjective effect; reconsider only if NAC-on bloodwork shows persistent oxidative stress or a GSH-deficiency genetic signal (GSTM1-null / GCLC / GCLM) emerges.

Glutathione (GSH) is a tripeptide of glutamate + cysteine + glycine and the body's primary intracellular thiol antioxidant. Its functional reactive group is the sulfhydryl (-SH) on the cysteine residue, which donates an electron to neutralize reactive oxygen species (ROS), conjugates with electrophiles for Phase II detox (GST enzyme family), and recycles vitamins C and E.

The oral GSH problem. Plain reduced glutathione has poor oral bioavailability (~<1% intact across the gut; Witschi 1992, Allen 2011) for two reasons:

1. Gastric and intestinal hydrolysis — γ-glutamyltransferase (GGT) and dipeptidases on the brush border cleave GSH into its component amino acids (glutamate, cysteine, glycine), so the body absorbs free amino acids rather than the intact tripeptide.
2. Hepatic first-pass — any intact GSH that does survive is largely degraded in the liver before reaching systemic circulation.

SAG's design. The acetyl group is attached to the sulfhydryl on cysteine (S-acetyl), shielding the thiol that would otherwise be the substrate for GGT and oxidation. This stabilizes the tripeptide through gastric pH and intestinal transit. The molecule is then absorbed intact (or largely intact), and the acetyl group is cleaved by cytoplasmic esterases inside cells, releasing free GSH at the intracellular site of action.

Plain English: Glutathione is the body's main detox antioxidant, but if you swallow it directly the gut chops it up. SAG puts a chemical "shield" on the reactive part so the molecule survives digestion, gets absorbed largely intact, then sheds the shield once inside the cell to release working glutathione.

Brain delivery — the contested part. The marketing claim is that SAG "easily crosses the blood-brain barrier" because it is more lipophilic than GSH. The pharmacokinetic data does not support this strongly. SAG is rapidly deacetylated in plasma and at the cell membrane — Fanelli 2018 found SAG itself was not quantifiable in any plasma sample after oral dosing, only the resulting free GSH. Once SAG is deacetylated, you are left with free GSH, which has the same poor BBB penetrance as exogenous GSH (a polar tripeptide that does not cross via passive diffusion; brain GSH is largely synthesized in situ from cysteine that does cross).

In contrast, N-acetyl-cysteine (NAC) crosses the BBB, is deacetylated to cysteine (the rate-limiting substrate for GSH synthesis), and supports brain GSH synthesis directly via the GCLC/GCLM enzyme complex inside neurons and astrocytes. This is the reason NAC, not SAG or liposomal GSH, has the stronger mechanistic and clinical case for brain glutathione support specifically.